Ulcostad

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ulcostad

Property Description
Active Ingredient Cimetidine
Form Tablet, Film-coated tablet
Pharmacological Class Histamine H2-receptor Antagonist (H2-blocker)
General Purpose Gastric acid secretion inhibitor
Origin Synthetic compound

Ulcostad: A Histamine H2-Receptor Antagonist

Ulcostad is a synthetic prescription medication whose single active ingredient is Cimetidine, primarily classified as a Histamine H2-receptor antagonist, or H2-blocker. This medication is administered through the oral route and is supplied as a tablet or film-coated tablet. Cimetidine is recognized in pharmacology as the first-generation agent in the H2-blocker class, setting the foundational standard for subsequent drugs of this type. The active ingredient serves as a therapeutic agent for addressing peptic ulcer disease and gastroesophageal reflux disease, and is used for managing acid-related digestive conditions. As a single-component product (monotherapy), Ulcostad's identity is focused on the established effects of Cimetidine.

How Does Ulcostad Work to Control Gastric Acid?

Ulcostad functions as an Antiulcer agent by precisely blocking specific receptors in the stomach lining to reduce the production of corrosive gastric acid. Its core mechanism involves the competitive inhibition of histamine at the H2-receptors found on the parietal cells, which are the main cellular "switches" that trigger acid release. This mechanism allows for therapeutic acid suppression. This means the medicine works by physically limiting the stomach's ability to produce high levels of acid. By achieving this inhibition of gastric acid secretion, Ulcostad creates a less hostile environment in the upper digestive tract. This action is clinically recognized for promoting the natural healing process for irritated mucosal tissues, such as those found during the management of an acute duodenal ulcer.

Regulatory References

  1. WHO Essential Medicines List
  2. WHO recognition

What side effects are possible with Ulcostad?

Possible Side Effects and Safety Information

The safety profile of Ulcostad (Cimetidine) is defined by official regulatory documents, classifying potential adverse reactions by frequency and the body system affected.

Frequency and System-Organ Classifications

Adverse reactions are grouped according to standard regulatory frequency bands and System-Organ-Classes (SOC).

Commonly documented effects (ge 1/100 to < 1/10) typically involve the nervous and gastrointestinal systems, and include headache, diarrhea, and tiredness.

Uncommon to Rare effects (le 1/100) may affect other systems, such as the blood (e.g., leukopenia, thrombocytopenia) and the liver (e.g., reversible increases in liver enzymes). Certain psychiatric effects like confusional states and hallucinations are classified as Uncommon.

Serious Adverse Reactions and Key Safety Patterns

Regulatory documents also detail Very Rare serious adverse reactions (< 1/10,000). These include severe conditions affecting the blood, such as agranulocytosis and aplastic anemia, as well as other serious events like acute pancreatitis and anaphylaxis.

Specific safety considerations are noted regarding the duration of use. Endocrine effects, such as gynecomastia and reversible impotence, are reported, particularly in association with prolonged treatment or high-dose regimens, and are typically reversible upon cessation of the medicine.

Population-Specific Safety Notes

The risk of specific adverse effects is explicitly noted to be higher in certain groups. Older adults and patients with renal impairment have an increased susceptibility to Central Nervous System (CNS) effects, including confusion. These effects are usually temporary and documented as reversible upon withdrawal of the medicine.

Overdose and Emergency Response

Overdose and When to Seek Help

The information in this section outlines the official, regulator-documented manifestations of Cimetidine (Ulcostad) overdose and the mandatory actions required as described in government prescribing information.

While regulatory reports note that Cimetidine is often considered very safe in overdose and may be asymptomatic even with high exposure, specific clinical manifestations are documented.

Documented Overdose Manifestations

System Documented Effects
Central Nervous System Confusion, agitation, delirium, drowsiness, hallucinations, slurred speech.
Cardiovascular System Abnormal heartbeat (arrhythmias) and low blood pressure.
Gastrointestinal System Diarrhea, nausea, and vomiting.

Official Emergency Actions

In case of any accidental or intentional overdose, it is mandated to seek professional assistance or contact a poison control center immediately.

Immediate medical help is required if the individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened. In such instances, emergency services must be called.

Management: Official guidance confirms that no specific antidote is available. Treatment is focused on symptomatic and supportive care, including close monitoring and maintaining cardiovascular status.

Population Note: There is an officially documented increased risk of severe CNS effects, such as confusion and delirium, in elderly patients and those with kidney impairment following an overdose.

Therapeutic Uses of Ulcostad

What Ulcostad Treats: Main Uses and Benefits

The areas where Ulcostad may offer support, focusing on symptom management and therapeutic benefits, are outlined below. This medication is commonly used to help with discomfort associated with conditions involving specific systemic and localized issues, such as gastric hypersecretion, peptic ulcer disease, and gastroesophageal reflux.


Managing Acute Symptom Discomfort and Distress

This medication is applied in clinical settings that involve symptoms related to physical discomfort that appear suddenly or intensify rapidly. It offers temporary assistance in short-term symptom management, which helps ease the overall symptom burden, particularly during acute phases of heightened distress.

It contributes to comfort during periods of heightened symptoms by helping patients cope more steadily with difficult symptom fluctuations.


Temporary Relief for Functional Strain

Ulcostad is considered relevant for conditions involving episodic or fluctuating manifestations, often linked to periods of increased physiological stress. It is applicable when symptoms that interfere with daily functioning cluster into patterns that create noticeable interference with routine activities and lead to temporary functional strain or discomfort. It provides supportive relief that assists with maintaining functional stability when symptoms become momentarily overwhelming.


Quick Fact: Relief for Heartburn and Indigestion

Regulatory References

  1. NIH StatPearls resource

Eligibility and Restrictions for Use

Who Can and Cannot Use Ulcostad?

This section describes the official population eligibility rules for Ulcostad (Cimetidine) based strictly on governmental regulatory documents.


Eligibility Exclusions and Restrictions

Classification Population/Condition
Absolute Contraindication Patients with known hypersensitivity to Cimetidine or any excipients must not use the medicine.
Not Recommended Use is not recommended during lactation/breastfeeding as the drug is secreted into human milk.
Age Restriction (OTC) Over-the-counter (OTC) use is not permitted for children under 12 years without the advice of a doctor.

Conditional Use and Special Populations

  • Impaired Organ Function: Use requires caution in patients with impaired renal function or hepatic impairment. Dosage must be reduced when kidney clearance falls below 50 ml/minute.
  • Older Adults: Advancing age (typically ge 50 years) is cited as a contributing factor for reversible Central Nervous System (CNS) effects, particularly with co-existing liver or kidney disease.
  • Pregnancy: Cimetidine is only recommended if clearly needed, and a physician determines that the potential benefits outweigh the risks.
  • Pediatric Use: While adults and adolescents ge 12 years are generally eligible, use in infants under 1 year is officially documented as not yet fully evaluated.

What should I know about interactions with other medicines?

Official Regulatory Interaction Profile

The interaction profile of Ulcostad is defined by its effects on drug clearance and absorption, resulting in mandated restrictions and requirements for co-administration, as documented in official prescribing information.

Classification Interacting Agents / Substances Official Regulatory Requirement
Contraindicated Combinations Dofetilide, Pimozide, Eliglustat, Lomitapide, and Fezolinetant Co-administration is formally prohibited due to high risk of increased blood concentration and toxicity.
Clinically Significant Increase in Exposure Warfarin, Theophylline, Phenytoin, Intravenous Lidocaine Cimetidine inhibits their metabolism, resulting in higher plasma levels. Requires close monitoring of affected drug concentrations.
Absorption Interference Ketoconazole, Iron Salts Reduced absorption of the co-administered drug due to Cimetidine's pH-raising effect. Requires administration time separation.

Pharmacokinetic Basis and Context

Ulcostad's principal interaction mechanism is the documented inhibition of hepatic microsomal Cytochrome P450 enzyme systems ( CYP1A2, CYP2C9, CYP2D6, and CYP3A4). This enzyme inhibition is the formal basis for the increased systemic exposure reported for numerous medicinal products, including certain TCAs and Benzodiazepines. Additionally, the label notes that the simultaneous administration of Antacids (aluminum/magnesium-containing) is not recommended as it may interfere with the absorption of Ulcostad itself; a two-hour separation is required when co-administration is necessary.

Regulatory documentation also highlights that the risk of central nervous system effects is greater in elderly patients and those with pre-existing liver or renal disease, representing a population-specific interaction consideration.

Mechanism of Action

Ulcostad functions as a selective proton pump inhibitor (PPI). The molecule, a lipophilic weak base, is a pro-drug that undergoes selective accumulation and acid activation within the highly acidic secretory canaliculi of the gastric parietal cells. The active form then forms a covalent and stable disulfide bond with accessible cysteine residues on the luminal surface of the H^+/ K^+-ATPase enzyme, commonly known as the proton pump.

This binding irreversibly inactivates the enzyme, thereby blocking the final common pathway for gastric acid production. This action results in a profound and prolonged reduction in both basal and stimulated gastric acid output regardless of the stimulus. The resulting elevation in intragastric pH serves to modulate the acidic environment, reducing the acid-dependent activity of proteases like pepsin within the stomach lumen.

Dosage and Administration Information

How Ulcostad is Used: Official Administration Guidelines

Ulcostad is administered primarily via the oral route as a tablet and is intended to be swallowed with water. The usage protocol is structured into specific dose amounts, daily frequency, and treatment duration, which varies between initial therapy and long-term prevention. The maximum daily dose for Cimetidine, the active ingredient, should generally not exceed 2.4 g (2400 mg), regardless of the condition being managed.

Standard Dosing Regimens and Frequency

Usage Pattern Typical Adult Regimen Frequency Duration
Acute Treatment (Ulcers) 800 mg once daily, OR 400 mg twice daily, OR 300 mg four times a day Once to four times daily Typically 4 to 8 weeks
Maintenance (Prevention) 400 mg Once daily at bedtime Long-term use reported

For multi-dose schedules, administration is commonly timed with meals and at bedtime. This medication may be used for symptom relief at a lower dose (200 mg), but self-treatment is limited to up to 14 days.

Population and Procedural Adjustments

Standard protocols require a dose reduction for patients with significantly impaired kidney function to prevent accumulation. In older adults, standard adult dosing may be used unless kidney function is compromised. Procedurally, before initiating treatment for a gastric ulcer, the possibility of malignancy should be excluded because the drug may mask symptoms, delaying necessary diagnosis. If a dose is missed, it is generally recommended to take it as soon as remembered, unless it is nearly time for the next scheduled dose, in which case the missed dose should be skipped.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Key Research Findings

Research explored whether the compound is associated with clinical outcomes in patients with this condition, such as duodenal and gastric ulcers, and gastroesophageal reflux disease. Studies examined whether the compound was linked to reductions in symptom severity by reducing gastric acid secretion.

  • Trial Outcomes: In one trial, the compound was associated with a decrease in the frequency of flare-ups. Another study evaluated the compound in combination with standard care for certain gastrointestinal disorders.
  • Comparative Studies: A comparative study evaluated outcomes between this compound and older treatment options, noting similar objective and subjective healing rates in ulcer patients.
  • Mechanism of Action: The compound is thought to influence the immune response and works as a competitive Histamine H2-receptor antagonist, blocking histamine's effect on the gastric parietal cells and thereby reducing acid secretion.

Dosage and Administration in Trials

The study protocol specified the timing of compound administration. Dosage levels varied across the different phases of research, with most trials focusing on a single, fixed dose to assess preliminary effects.

  • Pediatric Trials: Evidence remains limited regarding the use of this compound in pediatric populations, with studies primarily focusing on adult subjects.

Safety and Tolerability Profile

Long-term studies have collected data on adverse events. Studies have reported findings related to both efficacy and adverse events.

  • Side Effects: The most frequently reported side effect was observed to resolve in most cases, including reports of diarrhea and rash. Less common, but significant, adverse events, such as reversible neurological symptoms or haematological effects, were observed in a small percentage of participants, particularly at higher doses.
  • Discontinuation: The rate of study participants discontinuing treatment due to adverse events was recorded in all major trials.

Frequently Asked Questions (FAQ)

Common questions about Ulcostad (FAQ)

Q: What is the main reason a doctor would prescribe Ulcostad?

Ulcostad (Cimetidine) is officially indicated for the short-term management of active peptic ulcers, including duodenal and benign gastric ulcers. It is also prescribed to treat specific pathological hypersecretory conditions and certain symptoms associated with gastroesophageal reflux disease (GERD). This information comes directly from the FDA label and regulatory documents regarding its approved uses.

Q: Is Ulcostad used to treat heartburn or indigestion?

Yes, the over-the-counter (OTC) version of Ulcostad is specifically indicated for the relief and prevention of heartburn. This relief is intended for symptoms associated with acid indigestion and sour stomach, according to the official product labeling.

Q: How quickly does Ulcostad usually start working?

Official product information indicates that the active ingredient, Cimetidine, is absorbed rapidly after it is taken orally. Peak blood levels are typically reached within a relatively short period, often between 45 and 90 minutes after administration.

Q: What is Ulcostad commonly used for?

The drug is primarily used to address active ulcers in the stomach and small intestine, as well as symptoms related to gastroesophageal reflux disease (GERD). This use relies on its ability to inhibit the secretion of gastric acid in the stomach, as described in official documents.

Q: Is Ulcostad the same kind of medicine as a PPI?

No, Ulcostad is not the same kind of medicine as a Proton Pump Inhibitor (PPI). Official documents classify Ulcostad (Cimetidine) as a Histamine H2-receptor antagonist, or H2-blocker. These two classes of medicines work through different physiological mechanisms to reduce stomach acid.

Q: What is the difference between Ulcostad and common antacids?

Regulatory documents explain that Ulcostad works by systematically reducing the total amount of acid the stomach produces. In contrast, common antacids work by neutralizing acid that has already been made in the stomach.

Q: Can Ulcostad cause unusual stomach discomfort?

Official safety data indicates that effects on the gastrointestinal system, such as diarrhea, are commonly reported. Less frequent gastrointestinal effects, including nausea, vomiting, or stomach pain, is reported to occur in some patients.

Q: Can taking Ulcostad affect my sleep?

Central Nervous System (CNS) effects like drowsiness or somnolence (sleepiness) have been reported in official adverse event data. Although these effects are generally reported as mild, they indicate that the medicine may potentially influence sleep patterns.

Q: Is Ulcostad known to interact with common over-the-counter pain relievers?

Cimetidine is known to influence the way the body processes certain co-administered medications. Official labeling mentions interactions with certain compounds found in common OTC pain relievers, such as Acetaminophen and Acetylsalicylic acid.

Q: Are there any specific vitamins or supplements that Ulcostad interacts with?

The official product labeling advises that Ulcostad has the potential to interact with a broad range of substances. For this reason, the label advises patients to inform their healthcare provider about all vitamins, minerals, and herbal or other supplements being used.

Q: Is Ulcostad safe for use in older adults?

Official warnings note that older patients, typically those over 50 years of age, are cited to have an increased susceptibility to certain side effects. This includes a greater risk of Central Nervous System (CNS) effects, particularly if existing kidney or liver problems are present.

Q: How does the official literature describe Ulcostad's effectiveness?

Official literature describes Ulcostad as reliably achieving a significant and long-lasting reduction in the stomach's acid output by blocking specific H2-receptors. This action is linked to promoting the natural healing process for ulcers and other acid-related tissue irritations.

Q: Is Ulcostad meant to be chewed or swallowed whole?

Regulatory guidelines for prescription tablets state that they should generally be swallowed whole with water. The official label advises against dividing, crushing, or chewing the tablets.

Q: What are people usually warned about before starting Ulcostad?

Before starting treatment for a gastric ulcer, regulatory warnings specify that the possibility of malignancy (cancer) should be excluded, as Ulcostad may mask symptoms. Regulatory warnings mention contacting a doctor immediately if serious symptoms like bloody stools, vomiting blood, or trouble swallowing occur.

Q: Does Ulcostad treat the underlying cause of the condition or just the symptoms?

Ulcostad works by inhibiting acid secretion, which promotes the healing of damaged tissues and reduces symptoms. Official sources do not generally classify it as a treatment for eradicating the underlying causes of certain ulcers, such as the H. pylori bacterium.

Q: How long does Ulcostad stay in a person’s system?

The time it takes for half the drug to be eliminated from the body, known as the half-life, is documented in regulatory sources. For Ulcostad (Cimetidine), this elimination half-life is stated to be approximately 2 hours.

Q: What does 'contraindication' mean in relation to Ulcostad?

A contraindication is a condition or factor that officially prohibits the use of the drug. For Ulcostad, this means the medicine is not recommended for use if a patient has a known allergy or hypersensitivity to Cimetidine or any other ingredient in the product.

Q: Does Ulcostad contain gluten or lactose?

The specific inactive ingredients, or excipients, used in the tablets can differ depending on the manufacturer. The drug label lists all inactive ingredients, which may include substances like lactose. Patients with known allergies to substances like lactose are advised to ask their pharmacist for the specific list for their product.

Q: Is there a maximum time frame for how long Ulcostad can be used?

Regulatory documents limit the duration of over-the-counter (OTC) use to a maximum of 14 days without consulting a health professional. Conversely, prescription use for maintenance therapy may be continued for much longer periods.

Q: Can Ulcostad be crushed or broken if swallowing is difficult?

Prescription tablets are designed to be swallowed whole, and official instructions advise patients not to crush or chew them. A liquid oral solution may be available as an alternative formulation.

Q: Does Ulcostad affect blood pressure readings?

While Ulcostad does not directly treat blood pressure, official interaction data notes that it can raise the blood concentration of certain heart and blood pressure medicines. This interaction carries a potential risk of increasing the effects of those other drugs, such as low blood pressure.

Q: What kind of monitoring is typically recommended for people taking Ulcostad?

Monitoring may be required for patients who have existing co-morbidities or who are using certain interacting medications. In these cases, close monitoring of the blood levels of the co-administered drug, such as blood thinners, may be necessary as directed by a healthcare professional.

Q: Why do some regulatory documents list caution for patients with heart issues?

Caution is listed in part because serious heart conditions, such as severe chest pain, can sometimes present symptoms that mimic heartburn, which Ulcostad treats. Separate from this, rare cardiovascular adverse events, such as bradycardia (a slowed heart rate), have been reported in official safety data for H2-receptor antagonists.

Q: Are there common signs that Ulcostad is working?

Ulcostad is intended to promote the healing of ulcers and provide relief from symptoms associated with acid-related conditions like heartburn. Patient-reported relief from pain or reduced frequency of acid symptoms may be an indicator that the medicine is having its intended effect.

Q: What does the drug label say about discontinuing the use of Ulcostad?

Official documents indicate that stopping the drug after successful short-term ulcer treatment will not necessarily prevent the condition from returning later. If a patient is using the OTC product and symptoms persist past 14 days, or if they plan to stop a prescribed regimen, consultation with a healthcare professional is noted.

Q: Can Ulcostad interact with herbal remedies like St. John's Wort?

The official product label advises telling your healthcare provider about all herbal products you are using. This is because Ulcostad affects the CYP450 enzyme system, which processes a wide range of substances including many herbal remedies.

Q: What is the purpose of the inactive ingredients listed in Ulcostad tablets?

The inactive ingredients are not the medicine itself but are included for several necessary functions. They help with the manufacturing process, ensure the tablet has the correct stability, and control the way the active ingredient (Cimetidine) is released in the body.

How should Ulcostad be stored and disposed of?

Ulcostad (Cimetidine) must be stored and disposed of according to specific regulatory requirements to maintain its stability and efficacy.

Storage Conditions

Official labeling requires Ulcostad tablets to be stored below 25 C or 30 C, depending on the regulatory market, and they must not be frozen or refrigerated. The product must be protected from light and moisture, necessitating storage in the original container and keeping it tightly closed.

For safety, the medication must always be kept out of the sight and reach of children.

Disposal Instructions

Expired or unused Ulcostad must be disposed of as pharmaceutical waste. Regulatory documents explicitly state that the product should not be disposed of in household waste or flushed down wastewater. Instead, the medicine should be returned to a pharmacy or discarded through an approved local pharmaceutical waste collection program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ulcostad found in:

A-Z Index: